r The fat surrounding blood vessels (perivascular adipose tissue or PVAT) releases vasoactive compounds that regulate vascular smooth muscle tone.
Introduction
Perivascular adipose tissue (PVAT) is positioned around blood vessels and is regarded as being distinct from the adventitia, in spite of an absence of a barrier between them. Compelling evidence in recent years has led to the view that PVAT is in fact an active secretory tissue which releases several bioactive signalling molecules, collectively termed adipokines, which are important in the control of vascular tone in both health and diseases (Fortuno et al. 2003; Havel, 2004; Thalmann & Meier, 2007; Yamawaki et al. 2010) . Several studies have suggested a vasorelaxant or, at least, anticontractile effect of various fat depots in the body, proposing a role for TNF-α, H 2 S, NO, adiponectin and other adipocyte-derived relaxant factors (ADFCs; Gao et al. 2007; Fang et al. 2009; Lynch et al. 2013; Virdis et al. 2015) . On the other hand, other studies have reported opposing effects of PVAT on vascular tone. Gao et al. (2006) proposed that PVAT could augment vasoconstriction induced by perivascular nerve stimulation of the rat superior mesenteric artery. They reported that superoxide production from NAD(P)H oxidase (Gao et al. 2006 ) and angiotensin II (Lu et al. 2010 ) are involved in PVAT-mediated potentiation of perivascular nerve stimulation-elicited contraction.
Prostanoids are cyclooxygenase metabolites of arachidonic acid that exert diverse physiological and pathological effects in different systems, including relaxation and contraction of vascular smooth muscle (Wright et al. 2001 ). According to their selectivity for the natural prostanoids, prostaglandins (PG) PGI 2 , PGD 2 , PGE 2 , PGF 2 and thromboxane A 2 (TXA 2 ), there are five main types of prostanoids receptors IP, DP, EP, FP and TP, respectively. Of these receptors, TP and FP have the ability to mediate vasocontraction, IP and DP generally mediate vasorelaxation, while, depending on receptor subtype, EP has the ability to induce both contraction (EP 1 and EP 3 ) and relaxation (EP 2 and EP 4 ) (Coleman et al. 1994) . Prostanoids released from PVAT have been shown to regulate vascular tone. For example, PGE 2 and PGI 2 released from PVAT surrounding human saphenous vein attenuates noradrenaline-induced contraction (Ozen et al. 2013) . Similarly, prostacyclin released from mouse carotid artery PVAT exerts vasorelaxant effects and protects against endothelial dysfunction (Chang et al. 2012) . In contrast, another study showed that aortic PVAT from mice is capable of releasing a cyclooxygenase (COX)-derived ADCF that becomes functionally of greater activity in obesity (Meyer et al. 2013) , although the identity of this COX metabolite is unknown.
Extensive epidemiological data have revealed the existence of a prominent sexual dimorphism in the incidences of primary vascular diseases that involve excessive vasoconstriction. Thus, among the strongest independent risk factors for coronary artery disease is male sex and a male to female ratio of approximately 2:1 is consistently observed (Nettleship et al. 2009 ). In contrast, migraine headache (Bartelink et al. 1993 ) and Raynaud's Disease (Voulgari et al. 2000) all occur in premenopausal women at rates as much as fourfold higher than in men. Furthermore, a previous study has indicated that oestrogen could upregulate the expression of COX-2 and thromboxane synthase in both endothelium and vascular smooth muscle, and upregulate the expression of TP receptors in smooth muscle of female rat aorta, leading to enhanced vasoconstrictor prostanoid function (Li et al. 2008) . However, to date, no study has determined whether there are sex differences in the regulation of vascular tone by PVAT.
In the porcine coronary artery, PVAT induces a contraction and enhances agonist and electrical fieldstimulated contractile responses (Owen et al. 2013) . However, the contractile agents involved in these responses are unknown. PVAT is a potential therapeutic target for controlling coronary artery tone. Therefore, in this present study, we determined whether cyclooxygenase-derived vasoconstrictor prostanoids play a role in PVAT-induced contractile responses and investigated whether there are sex differences in the response of the coronary artery to PVAT.
Methods

Preparing of rings of porcine coronary arteries
Hearts from male and female pigs (large white hybrid pigs, 4-6 months old, weighing ß50 kg) were obtained from a local abattoir licenced under the current Welfare of Animals (Slaughter or Killing) Regulations and transported back to the laboratory in ice-cold modified Krebs-Henseleit solution (118 mM NaCl, 4.8 mM KCl, 1.1 mM MgSO 4 , 25 mM NaHCO 3 , 1.2 mM KH 2 PO 4 , 12 mM D-glucose, 1.25 mM CaCl 2 ). Arteries were collected at random and the females were randomly distributed throughout the 18-21 day oestrus cycle. Therefore, there would be no bias as the stage of the cycle. The anterior proximal part of the coronary artery was then dissected and placed in Krebs-Henseleit solution pre-gassed with 5% CO 2 and 95% O 2 . PVAT was carefully removed and maintained in Krebs-Henseleit solution until further use. Thereafter, coronary arteries were cut into rings of approximately 5 mm in length and suspended in a multichannel 5 ml organ bath setup. Each bath was filled with 5 ml of Krebs-Henseleit solution and maintained at 37°C and constantly gassed with carbogen (95% O 2 , 5% CO 2 ). Tension was measured and recorded using isometric force transducers connected to a Powerlab data acquisition system (ADInstruments) via an amplifier.
Characterization of vascular responses of porcine isolated coronary arteries
The arteries were initially set to 8 g of tension, determined from preliminary studies, and then left to equilibrate for approximately 30-45 min. Once a stable baseline was attained, two consecutive responses to 60 mM KCl were obtained for standardization. Relevant test compounds were then added with 60 min incubation time. The following test compounds were used: melittin (10 μM) to stimulate PLA 2 activity (Koumanov et al. 2003) ; indomethacin (10 μM) (Malinowski et al. 2008 ) and flurbiprofen (10 μM) (Stanley & O'Sullivan, 2014) to determine the role of cyclooxygenase. To study the role of specific prostanoids, GR32191B (3 μM) (He & Yang, 1999) and AL8810 (10 μM) (Ramos-Alves et al. 2012) were used as antagonists of TP and FP receptors, respectively. Ethanol or DMSO (0.1% v/v) were used as vehicle controls, as appropriate. Of note, there was no obvious difference in the amount of PVAT per unit length of coronary artery between female and male. After incubation of the coronary artery segments with test compounds, 0.3 g PVAT was added to the organ baths and contractile responses measured.
In a separate series of experiments, cumulative concentration-response curves for the TXA 2 agonist U46619 (1-300 nM) or PGF 2α (0.1-100 μM) were constructed in coronary artery segments from male and female pigs.
Determination of levels of TXB 2 and PGF 2α by ELISA Levels of TXB 2 , a stable metabolite of TXA 2, and PGF 2α in PVAT were determined by ELISA. PVAT (0.3 g) was homogenised in either 0.1 M potassium phosphate buffer (pH 7.4) for TXB 2 estimation, or Tris-buffered saline containing 0.1% (v/v) Tween 20 for PGF 2α estimation, along with protease inhibitor cocktail (Calbiochem) and indomethacin (10 μM). The amount of TXB 2 and PGF 2α in PVAT samples from male and female animals was analysed by ELISA (ab133022 and ab133041; Abcam, Cambridge, UK), according to the instructions of the manufacturer. TXB 2 and PGF 2α were detected colorimetrically using an alkaline phosphatase (AP) conjugated secondary antibody with para-Nitrophenylphosphate (pNpp) as substrate. Colour intensity produced was determined by reading at 405 nm using a SpectraMAX 340 PC microplate reader (Molecular Devices, Wokingham, Berks, UK). The results were expressed as picograms per microgram of total protein.
Assessment of the PVAT-released TXB 2 by ELISA
Porcine coronary arterial PVAT from each sex was dissected, weighed and added to an Eppendorf tube containing 1 ml pre-gassed Krebs-Henseleit solution, at 37°C. For consistency with the functional studies, PVAT was incubated for 2.5 h with and without melittin (10 μM) in order to investigate the effect of activation of PLA 2 on the level of TXB 2 released from PVAT. The level of TXB 2 in the Krebs-Henseleit solution was then determined using ELISA (as described above) and the data normalized for weight of PVAT.
Estimation of TP and FP receptor expression in coronary arteries by Western immunoblotting
Western immunoblotting was performed to determine the expression of TP and FP receptors in segments of coronary arteries from female and male pigs. Arteries were finely dissected from the adherent PVAT and connective tissue and homogenized on ice using Tris buffer (pH 7.4) with protease inhibitor cocktail (Calbiochem, VWR International Ltd, Lutterworth, Leics, UK). After estimation of the protein content of each sample using the Lowry method, 6× Laemmli sample buffer was added to the samples. Samples were subsequently boiled at 100°C for 5 min and centrifuged at 13,000 g for 1 min. Stock solutions (20 μg per well) were run on 4-20% gradient polyacrylamide gradient gels (Bio-Rad, Hemel Hempstead, Herts, UK). Proteins were then transferred onto nitrocellulose membrane (GE Healthcare, Little Chalfont, Bucks, UK) by Western blotting, and then the membrane blocked with 5% (w/v) non-fat milk in Tris-buffered saline containing 0.1% v/v Tween 20 (TBST) at room temp for 1 h. The blot was then incubated with either rabbit anti-TXA 2 receptor antibody (1:250 dilution; ab188897, Abcam, Cambridge, UK) or rabbit anti-PGF 2α receptor antibody (1:250 dilution; orb185891; Biorbyt, Cambridge, UK) in 5% milk in TBST overnight at 4°C with shaking. An anti-mouse myosin light chain (MLC) antibody was also included as a loading control (1:1000 dilution; Sigma-Aldrich, Poole, Dorset, UK). The following day, the blot was washed in TBST followed by incubation for 1 h with IRDye 800CW goat anti rabbit (1:10,000) and IRDye 680CW goat anti-mouse (1:10,000) secondary antibodies (IRDye, Licor, Cambridge, UK). Immunoblot was then visualized using an Odyssey system from Licor.
Materials
All drugs were purchased from Sigma-Aldrich except for AL8810 from Santa Cruz Biotechnology and PGF 2α from Cayman Chemicals. Stock solutions of flurbiprofen, PGF 2α and GR32191B were dissolved in dimethyl sulfoxide (DMSO). Stock solution of indomethacin and AL8810 were dissolved in absolute ethanol whereas melittin was dissolved in distilled water. Stock solutions of U46619 were made to 10 mM in ethanol. All further dilutions of the stock solutions were made using distilled water.
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Statistical analysis
Data are expressed as means ± SEM, where n = the number of different animals. The concentration-response curves were fitted to a sigmoidal curve with a variable slope using four parameters logistic equation using GraphPad Prism software. The maximum percentage contraction (R max ) and the negative log of concentration required to produce half the maximal contraction of the induced tone (pEC 50 ) were calculated from the fitted curves. Data were tested for normality using a Shapiro-Wilk test.
Comparisons between two groups of data were analysed using two-tailed, paired or unpaired Student's t test, as appropriate. The effects of enzyme inhibitors and receptor antagonists on the PVAT-induced contraction over time were analysed using a two-way ANOVA in conjunction with the Sidak's post hoc test to assess possible difference at individual concentrations. A P value <0.05 was considered to be statistically significant. Statistical analysis was performed by GraphPad Prism (Version 6).
Results
Effects of addition of PVAT on vascular tone of female and male PCAs
Addition of 0.3 g PVAT caused a time-dependent increase in tone compared to time controls in coronary artery segments from both female and male PCAs (Fig. 1) . There was inter-individual variation in the size of the contractile response to PVAT therefore adjacent coronary arterial segments from the same animal were always used as controls.
Role of prostanoids in PVAT-induced contraction
Addition of the cyclooxygenase inhibitors indomethacin and flurbiprofen (both 10 μM) had no effect on basal tone. However, they caused a significant inhibition in the contraction to PVAT compared to control in both sexes (Fig. 2) . The thromboxane receptor antagonist GR32191B (3 μM) caused a partial reduction in the PVAT-induced contraction in coronary arteries from female animals (Fig. 3A) , whereas the responses of coronary arteries from male animals to PVAT were unaffected by GR32191B (Fig. 3B) . As the TP receptor antagonist had no effect on the PVAT contraction in males, we determined the effect of a FP receptor antagonist. In contrast to the effect of TP receptor antagonism, the FP receptor antagonist AL8810 had no significant effect on the PVAT-induced contraction in coronary arteries from female animals, but reduced the contraction in coronary arteries from male animals ( Fig. 3C and D) . animals could be due to differences in the content of thromboxane and PGF 2α in the PVAT, levels of the stable thromboxane metabolite TXB 2 , and PGF 2α in PVAT were determined by ELISA. Both TXB 2 and PGF 2α were detected in the PVAT from the coronary artery. However, there was no significant difference in the level of TXB 2 or PGF 2α in coronary artery PVAT from female and male animals (Fig. 4) .
Determination of the level of TP and FP receptor expression in PCAs
As there were no differences in the levels of TXB 2 or PGF 2α in PVAT from male and female animals, we determined whether there were differences in the expression of the receptors on the coronary artery, which might explain the differences in the role of these prostanoids. Western immunoblotting for the TP receptor identified a band at the predicted molecular weight of 40 kDa. When expressed as a ratio to myosin light chains, used as a loading control, there was no difference in the level of expression of TP receptor between coronary arteries from male and female animals ( Fig. 5A and B) . Western immunoblotting also detected a band at 50 kDa for the FP receptor. In this case, there was a significantly higher level of expression of the FP receptor in coronary arteries from male animals compared to female animals ( Fig. 5D and E) .
Assessment of the responsiveness of PCAs to TXA 2 and PGF 2α
As our data indicate differences in the role of TP and FP receptors in the PVAT-induced contractions in coronary arteries from male and female animals, which cannot be explained by differences in the content of thromboxane and PGF 2α in the fat, we determined whether there are differences in the contractions in response to TP or FP receptor activation, in the absence of PVAT. There was no difference in the response of PCAs to the TXA 2 mimetic U46619 between female and male pigs (Fig. 5C ). On the other hand, the contractile responses to PGF 2α were significantly greater in arteries from male pigs (Fig. 5F ).
Effect of phospholipase A 2 stimulation on PVAT-induced contractions
Our data indicate that cyclooxygenase-produced prostanoids play a role in the PVAT-induced contraction in coronary artery segments from both sexes (Fig. 6) . The TP antagonist GR32191B caused complete inhibition of the PVAT-induced contraction in the presence of melittin in arteries from female animals and partial inhibition in arteries from male animals ( Fig. 6C and D) . Surprisingly, the FP receptor antagonist AL8810 had no effect on the PVAT-induced contractions in arteries from male or female animals ( Fig. 6E and F) . However, in subsequent experiments, we demonstrated that pre-incubation with melittin results in desensitisation of the FP receptor, but not TP receptor-mediated contraction, as addition of U46619 and PGF 2α to the PCA after pre-incubation with melittin resulted in a contractile response to U46619 but not PGF 2α ( Fig. 7A and B) .
Determination of the release of TXB 2 from PVAT
Although there was no difference in the level of TXB 2 in the PVAT from male and female animals, we explored the possibility that there are differences in the release of 
MLC (20KDa) TP (40KDa) MLC ( thromboxane from PVAT. Therefore, we determined the levels of TXB 2 in the buffer after incubation with PVAT. In these experiments it was found that the concentration of TXB 2 was higher in the buffer after incubation with PVAT from female animals compared to PVAT from male animals (Fig. 8A) . The level of TXB 2 released from PVAT was significantly potentiated after addition of the PLA 2 stimulator (melittin) in both females and males ( Fig. 8B  and C) .
Discussion
The recognition that perivascular adipose tissue is not simply a reservoir for lipid storage but is also a complex endocrine organ, has led to a substantial research effort to establish the mechanistic links between the PVAT and vascular tone regulation. It is becoming increasingly clear that there are differences in the vascular responsiveness in males compared to females (Bubb et al. 2012) . For Data are expressed as change in tone per gram weight and are means ± SEM of 5 animals. E and F, effect of pre-incubation with the FP receptor antagonist AL8810 (10 μM) on the PVAT-induced contraction, in the absence or presence of melittin (10 μM). Data are expressed as change in tone per gram weight and are means ± SEM of 4 female (E) and 5 male (F) animals. * P < 0.05, * * P < 0.01 and * * * P < 0.001 (two-way ANOVA followed by a Sidak's post hoc test).
example, we have identified differences in endothelial function between the sexes (Wong et al. 2015) . In this present study, we have identified that the PVAT-induced contraction in the porcine coronary artery is mediated, at least in part, through the prostanoids thromboxane and PGF 2α . Although both prostanoids are present in PVAT, there are sex differences in the vasomotor response of the coronary arteries to PVAT, in that TXA 2 and PGF 2α antagonists reduced the PVAT-induced vasoconstriction in females and males, respectively. Re-addition of PVAT to segments of porcine coronary artery produced a contractile response, which is in line with previous studies, indicating that coronary artery PVAT releases adipose-derived contractile factors (ADCFs; Owen et al. 2013) . However, this previous study did not identify the factor causing the contractile response. In this present study, we have demonstrated that the contraction in response to re-addition of PVAT was partially inhibited by cyclooxygenase inhibitors, indicating a role for contractile prostanoids. Furthermore, the contraction was inhibited by prostanoid receptor antagonists, providing further support for involvement of prostanoids in the contractile response. Interestingly, the contractile response to coronary artery PVAT from female animals was inhibited by a TP receptor antagonist, whereas the contractile response to coronary artery PVAT from male arteries was inhibited by a FP receptor antagonist. These data suggest sex differences in the prostanoids mediating the contractile response.
The role of a cyclooxygenase product in the PVATinduced contraction is similar to that seen in mouse aorta, although, in that particular study, only thromboxane levels were measured (Meyer et al. 2013) . In this present study we have demonstrated the presence of thromboxane in the PVAT from porcine coronary artery, although there was no difference in the levels of this prostanoid between male and female animals. In addition, a concentration-response curve with a TXA 2 agonist (U46619) was performed to assess the responsiveness of PCAs to TXA 2 in both sexes and showed no difference in the response of coronary rings from different sexes to TXA 2 . Moreover, Western blot analysis found no difference in TP expression between female and male coronary arteries. These data indicate that the sex differences in the role of thromboxane in the PVAT-induced contraction cannot be attributable to either differences in TP receptor expression or coupling of the receptor to intracellular signalling pathways mediating contraction. We therefore determined whether there are differences in the release of thromboxane from the PVAT by measuring the levels of TXB 2 in the buffer. Interestingly, there was a greater amount of TXB 2 in the buffer containing PVAT from female animals compared to males, suggesting that, although levels of thromboxane are the same in PVAT from both sexes, a greater amount of thromboxane is actually released from the PVAT in females. Although the exact reason for the difference in release of TXB 2 has not been addressed in this study, many reasons can be postulated such as a difference in the expression or function of TXB 2 transporters (for example, multidrug resistance protein 4 or other prostaglandin transporters), which act as a prostanoid efflux pumps (Schuster, 2002; Reid et al. 2003; Rius et al. 2005) , or differences in the turnover of released TXB 2 . However, the data explain why the PVAT-induced contraction in coronary arteries J Physiol 595.21 from female animals is inhibited by the TP receptor antagonist.
The present study also provides evidence that PGF 2α is expressed in the PVAT of the coronary artery and is involved in the PVAT-induced contraction in male pigs, as FP receptor antagonism by AL8810 significantly reduced the resultant vasocontraction. Therefore, like thromboxane, PGF 2α has a role as a PVAT-derived contractile agent. Although there was no difference in the level of PGF 2α in the PVAT from male and female pigs, PGF 2α itself produced a greater contractile response in coronary arteries from male animals compared to females. This corresponds with a greater expression of the FP receptor in coronary arteries from male animals. Therefore, the sensitivity of the PVAT-induced contraction to FP receptor antagonism in coronary arteries from male animals, but not females, could be explained by differences in FP receptor expression.
Although the functional experiments with the receptor antagonists GR32191B and AL8810 are consistent with the responses in males being mediated by FP receptors and those in females by TP receptors, when we carried out a three-way analysis of variance to assess the sex differences these did not reach statistical significance. It is likely that the lack of significant sex differences in the functional experiments was due to the limited power of the experiments to detect sex differences. However, when viewed alongside the receptor expression studies, our data are consistent with receptor differences between males and females contributing towards the sex differences.
In order to confirm the role of prostanoids in the PVAT-induced contraction in the coronary artery, we determined the effect of the PLA 2 activator melittin. Melittin enhanced the PVAT-induced contraction in coronary arteries from both sexes, which correlates with the role of the PLA 2 -arachidonic acid-cyclooxygenase pathway. Furthermore, melittin enhanced the production of thromboxane within PVAT and the level of thromboxane released from the PVAT. Antagonism of TP receptors inhibited the contraction in response to Data are expressed as a picograms of TXB 2 released per millilitre per gram of PVAT and are means ± SEM of 10 female and 9 male PVAT samples. * P < 0.05 (two-tailed, unpaired Student's t test). B and C, comparison of the levels of TXB 2 in the buffer after a 2.5 h incubation with PVAT with and without melittin (10 μM) from female (B) or male (C) pigs. Data are expressed as picograms of TXB 2 released per millilitre per gram PVAT and are means ± SEM of 6 female and 7 male PVAT samples. * P < 0.05, * * P < 0.01 (two-tailed, paired Student's t test) versus paired controls.
PVAT in coronary arteries from both male and female animals. Interestingly, the FP antagonist no longer inhibited the PVAT-induced contractions in either male or female arteries. However, we found that melittin caused desensitisation of the PGF 2α -induced contraction but not the TXA 2 -induced contraction, as there was no contraction in response to PGF 2α in PCA segments pre-incubated with melittin, whereas the contraction in response to the thromboxane mimetic U46619 was maintained. This finding could explain the lack of effect of the FP antagonist under these conditions. A limitation of our study is the potential selectivity of GR32191B for TP receptors over FP receptors. However, our data indicate that the larger inhibition of the PVAT response seen with AL8810 in PCAs from males is likely to be due to greater responsiveness and FP receptor expression in males compared to females. Similarly, the greater effect of GR32191B on PVAT responses in females compared to males appears to be due to greater release of thromboxane.
In conclusion, these data demonstrate that PVAT is able to regulate porcine coronary arterial tone through the release of thromboxane and PGF 2α . To the best of our knowledge, this is the first study that identifies sex differences in PVAT-induced regulation of vascular tone, namely that a thromboxane antagonist inhibits PVAT-dependent vasoconstriction in females while a PGF 2α antagonist is able to inhibit the contraction of PCAs from males. The variation in the roles of TXA 2 and PGF 2α between the sexes is further supported by the findings of a greater release of thromboxane from PVAT from female animals and greater expression of FP receptors on the porcine coronary artery from males. It is clear that there are sex differences in the regulation of vascular tone, including the role of endothelium-derived hyperpolarization (Wong et al. 2014) . The data presented here enhance our knowledge of the mechanisms underlying these sex differences by demonstrating differences in the adipose-derived contractile factors released from coronary artery PVAT. Adipose tissue, including PVAT, changes under pathological conditions such as obesity. In the porcine coronary artery, obesity enhances the contractile responses of PVAT (Owen et al. 2013) . Whether this is due to altered release of prostanoids is unknown. Furthermore, whether the sex difference in the release of prostanoids is maintained in obesity is unknown. Future studies should explore whether these sex differences in PVAT are maintained under pathological conditions.
